"The U.S. Food and Drug Administration today approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or f"...
Mechanism Of Action
Nevirapine is an antiviral drug [see Microbiology].
Pharmacokinetics - Adults
Absorption and Bioavailability
The single-dose pharmacokinetics of VIRAMUNE XR was studied in 17 healthy volunteers. Nevirapine was absorbed with a median tmax of approximately 24 hrs. The mean Cmax and AUC0-∞ of nevirapine were 2060 ng per mL and 161,000 ng*hr/mL, respectively. The bioavailability of 400 mg of VIRAMUNE XR, relative to 400 mg of immediate-release VIRAMUNE, was approximately 75%.
The multiple-dose pharmacokinetics of VIRAMUNE XR was studied in 24 HIV-1 infected subjects who switched from chronic VIRAMUNE IR to VIRAMUNE XR. The mean nevirapine AUC0-24,ss and Cmin,ss after 19 days of VIRAMUNE XR dosing under fasted conditions were 82,000 ng*hr/mL and 2920 ng per mL, respectively. When VIRAMUNE XR was administered under fed conditions, the mean nevirapine AUC0-24,ss and Cmin,ss were 96,700 ng*hr/mL and 3150 ng per mL, respectively. The bioavailability of 400 mg of VIRAMUNE XR, relative to 400 mg of immediate-release VIRAMUNE, under fasted and fed conditions, was 80% and 94%, respectively. The difference in the bioavailability of nevirapine, when VIRAMUNE XR is dosed under fasted or fed conditions, is not considered clinically relevant. VIRAMUNE XR can be taken with or without food.
In single-dose, parallel-group bioavailability trial (1100.1517) in adults, the VIRAMUNE XR 100 mg tablet exhibited extended-release characteristics of prolonged absorption and lower maximal concentration, as compared to the immediate-release VIRAMUNE 200 mg tablet.
Nevirapine is highly lipophilic and is essentially nonionized at physiologic pH. Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans. Nevirapine readily crosses the placenta and is also found in breast milk [see Use In Specific Populations]. Nevirapine is about 60% bound to plasma proteins in the plasma concentration range of 1-10 mcg per mL. Nevirapine concentrations in human cerebrospinal fluid (n=6) were 45% (±5%) of the concentrations in plasma; this ratio is approximately equal to the fraction not bound to plasma protein.
In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 (oxidative) metabolism to several hydroxylated metabolites. In vitro studies with human liver microsomes suggest that oxidative metabolism of nevirapine is mediated primarily by cytochrome P450 (CYP) isozymes from the CYP3A and CYP2B6 families, although other isozymes may have a secondary role. In a mass balance/excretion trial in eight healthy male volunteers dosed to steady state with immediate-release VIRAMUNE 200 mg given twice daily followed by a single 50 mg dose of 14C-nevirapine, approximately 91.4 ± 10.5% of the radiolabeled dose was recovered, with urine (81.3 ± 11.1%) representing the primary route of excretion compared to feces (10.1 ± 1.5%). Greater than 80% of the radioactivity in urine was made up of glucuronide conjugates of hydroxylated metabolites. Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (less than 5%) of the radioactivity in urine (representing less than 3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
Nevirapine is an inducer of hepatic cytochrome P450 (CYP) metabolic enzymes 3A and 2B6. Nevirapine induces CYP3A and CYP2B6 by approximately 20-25%, as indicated by erythromycin breath test results and urine metabolites. Autoinduction of CYP3A and CYP2B6 mediated metabolism leads to an approximately 1.5- to 2fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200-400 mg per day of immediate-release VIRAMUNE. Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25-30 hours following multiple dosing with 200-400 mg per day.
HIV-1 seronegative adults with mild (CrCL 50-79 mL per min; n=7), moderate (CrCL 30-49 mL per min; n=6), or severe (CrCL less than 30 mL per min; n=4) renal impairment received a single 200 mg dose of immediate-release VIRAMUNE in a pharmacokinetic trial. These subjects did not require dialysis. The trial included six additional subjects with renal failure requiring dialysis.
In subjects with renal impairment (mild, moderate or severe), there were no significant changes in the pharmacokinetics of nevirapine. However, subjects requiring dialysis exhibited a 44% reduction in nevirapine AUC over a one-week exposure period. There was also evidence of accumulation of nevirapine hydroxy-metabolites in plasma in subjects requiring dialysis. An additional 200 mg dose of immediate-release VIRAMUNE following each dialysis treatment is indicated [see DOSAGE AND ADMINISTRATION and Use in Specific Populations]. VIRAMUNE XR has not been studied in patients with renal dysfunction.
In a steady-state trial comparing 46 subjects with mild (n=17; expansion of some portal areas; Ishak Score 1-2), moderate (n=20; expansion of most portal areas with occasional portal-to-portal and portal-to-central bridging; Ishak Score 3-4), or severe (n=9; marked bridging with occasional cirrhosis without decompensation indicating Child-Pugh A; Ishak Score 5-6) fibrosis as a measure of hepatic impairment, the multiple dose pharmacokinetic disposition of nevirapine and its five oxidative metabolites were not altered. However, approximately 15% of these subjects with hepatic fibrosis had nevirapine trough concentrations above 9,000 mcg per mL (2-fold the usual mean trough). Therefore, patients with hepatic impairment should be monitored carefully for evidence of drug-induced toxicity [see WARNINGS AND PRECAUTIONS]. The subjects studied were receiving antiretroviral therapy containing immediate-release VIRAMUNE 200 mg twice daily for at least 6 weeks prior to pharmacokinetic sampling, with a median duration of therapy of 3.4 years.
In a pharmacokinetic trial where HIV-1 negative cirrhotic subjects with mild (Child-Pugh A; n=6) or moderate (Child-Pugh B; n=4) hepatic impairment received a single 200 mg dose of immediate-release VIRAMUNE, a significant increase in the AUC of nevirapine was observed in one subject with Child-Pugh B and ascites suggesting that patients with worsening hepatic function and ascites may be at risk of accumulating nevirapine in the systemic circulation. Because nevirapine induces its own metabolism with multiple dosing, this single-dose trial may not reflect the impact of hepatic impairment on multiple-dose pharmacokinetics.
Do not administer nevirapine to patients with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and Use in Specific Populations]. VIRAMUNE XR has not been evaluated in patients with hepatic impairment.
In the multinational 2NN trial of immediate-release VIRAMUNE, a population pharmacokinetic substudy of 1077 subjects was performed that included 391 females. Female subjects showed a 13.8% lower clearance of nevirapine than did men. Since neither body weight nor Body Mass Index (BMI) had an influence on the clearance of nevirapine, the effect of gender cannot solely be explained by body size.
The effects of gender on the pharmacokinetics of VIRAMUNE XR have been investigated in Trial 1100.1486. Female subjects tend to have higher (approximately 20 30%) trough concentrations in both VIRAMUNE XR and immediate-release VIRAMUNE treatment groups.
An evaluation of nevirapine plasma concentrations (pooled data from several clinical trials) from HIV-1-infected subjects (27 Black, 24 Hispanic, 189 Caucasian) revealed no marked difference in nevirapine steady-state trough concentrations (median Cminss = 4.7 mcg per mL Black, 3.8 mcg per mL Hispanic, 4.3 mcg per mL Caucasian) with long-term treatment with immediate-release VIRAMUNE at 400 mg per day. However, the pharmacokinetics of nevirapine have not been evaluated specifically for the effects of ethnicity.
Black subjects (n=80/group) in Trial 1100.1486 showed approximately 30 to 35% higher trough concentrations than Caucasian subjects (250-325 subjects/group) in both immediate-release VIRAMUNE and VIRAMUNE XR treatment groups over 96 weeks of treatment at 400 mg per day.
Nevirapine pharmacokinetics in HIV-1-infected adults do not appear to change with age (range 18–68 years); however, nevirapine has not been extensively evaluated in patients beyond the age of 65 years [see Use in Specific Populations].
The pharmacokinetics of VIRAMUNE XR were assessed in HIV-1 infected children 3 to less than 18 years of age. Children enrolled received weight or body surface area dose-adjusted immediate-release VIRAMUNE in combination with other antiretrovirals for a minimum of 18 weeks and then were switched to VIRAMUNE XR tablets in combination with other antiretrovirals for 10 days, after which steady-state pharmacokinetic parameters were determined.
Overall, the mean systemic nevirapine exposures in children 6 to less than 18 years of age following administration of VIRAMUNE XR and immediate-release VIRAMUNE were similar. Based on intensive PK data (N=17), the observed geometric mean ratios of VIRAMUNE XR to immediate-release VIRAMUNE were approximately 97% for Cmin,ss and 94% for AUCss with 90% confidence intervals within 80% - 125%; the ratio for Cmax,ss was lower and consistent with a once daily extended-release dosage form.
Trial 1100.1518 did not provide sufficient pharmacokinetic data for children 3 to less than 6 years of age to support the use of VIRAMUNE XR in this age group.
[see DRUG INTERACTIONS]
Nevirapine induces hepatic cytochrome P450 metabolic isoenzymes 3A and 2B6. Co-administration of VIRAMUNE XR and drugs primarily metabolized by CYP3A or CYP2B6 may result in decreased plasma concentrations of these drugs and attenuate their therapeutic effects.
While primarily an inducer of cytochrome P450 3A and 2B6 enzymes, nevirapine may also inhibit this system. Among human hepatic cytochrome P450s, nevirapine was capable in vitro of inhibiting the 10-hydroxylation of (R)-warfarin (CYP3A). The estimated Ki for the inhibition of CYP3A was 270 micromolar, a concentration that is unlikely to be achieved in patients as the therapeutic range is less than 25 micromolar. Therefore, nevirapine may have minimal inhibitory effect on other substrates of CYP3A.
Nevirapine does not appear to affect the plasma concentrations of drugs that are substrates of other CYP450 enzyme systems, such as 1A2, 2D6, 2A6, 2E1, 2C9, or 2C19.
Table 5 (see below) contains the results of drug interaction trials performed with immediate-release VIRAMUNE and other drugs likely to be co-administered. The effects of nevirapine on the AUC, Cmax, and Cmin of co-administered drugs are summarized. Results of drug interaction studies with immediate-release VIRAMUNE are expected to also apply to VIRAMUNE XR.
Table 5 : Drug Interactions: Changes in
Pharmacokinetic Parameters for Co-administered Drug in the Presence of
Immediate-Release VIRAMUNE (All interaction studies were conducted in HIV-1
|Co-administered Drug||Dose of Coadministered Drug||Dose Regimen of immediate-release VIRAMUNE||n||% Change of Co-administered Drug Pharmacokinetic Parameters
|Atazanavir/ Ritonavira, d||300/100 mg QD day 4–13, then 400/100 mg QD, day 14–23||200 mg BID day 1-23. Subjects were treated with nevirapine prior to trial entry.||23||Atazanavir 300/100 mg
(↓52 to ↓29)
|Atazanavir 300/100 mg
(↓40 to ↓14)
|Atazanavir 300/100 mg
(↓80 to ↓60)
|Atazanavir 400/100 mg
(↓35 to ↑2)
|Atazanavir 400/100 mg ↑2
|Atazanavir 400/100 mg
(↓73 to ↓40)
|Darunavir/ Ritonavire||400/100 mg BID||200 mg BID||8||↑24
(↓3 to ↑57)
(↑14 to ↑73)
(?21 to ↑32)
|Didanosine||100-150 mg BID||200 mg QD x 14 days; 200 mg BID x 14 days||18||⇔||⇔||§|
|Efavirenza||600 mg QD||200 mg QD x 14 days; 400 mg QD x 14 days||17||↓28
(↓34 to ↓14)
(↓23 to ↑1)
(↓35 to ↓19)
|Fosamprenavir||1400 mg BID||200 mg BID. Subjects were treated with nevirapine prior to trial entry.||17||↓33
(↓45 to ↓20)
(↓37 to ↓10)
(↓50 to ↓15)
|Fosamprenavir/ Ritonavir||700/100 mg BID||200 mg BID. Subjects were treated with nevirapine prior to trial entry||17||↓11
(↓23 to ↑3)
(↓32 to ↓4)
|Indinavira||800 mg q8H||200 mg QD x 14 days; 200 mg BID x 14 days||19||↓31
(↓39 to ↓22)
(↓24 to ↓4)
(↓53 to ↓33)
|Lopinavira, b||300/75 mg/m²
(lopinavir/ ritonavir) b
|7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week||12, 15 c||↓22
(↓44 to ↑9)
(↓36 to ↑16)
(↓75 to ↓19)
|Lopinavira||400/100 mg BID
|200 mg QD x 14 days; 200 mg BID >1 year||22, 19 c||↓27
(↓47 to ↓2)
(↓38 to ↑5)
(↓72 to ↓26)
|Maraviroc f||300 mg SD||200 mg BID||8||↑1
(↓35 to ↑55)
(↓6 to ↑151)
|Nelfinavira||750 mg TID||200 mg QD x 14 days; 200 mg BID x 14 days||23||⇔||⇔||↓32
(↓50 to ↑5)
(↓70 to ↓53)
(↓68 to ↓48)
(↓74 to ↓55)
|Ritonavir||600 mg BID||200 mg QD x 14 days; 200 mg BID x 14 days||18||⇔||⇔||⇔|
|Stavudine||30-40 mg BID||200 mg QD x 14 days; 200 mg BID x 14 days||22||⇔||⇔||⇔|
|Zalcitabine||0.125-0.25 mg TID||200 mg QD x 14 days; 200 mg BID x 14 days||6||⇔||⇔||⇔|
|Zidovudine||100-200 mg TID||200 mg QD x 14 days; 200 mg BID x 14 days||11||↓28
(↓40 to ↓4)
(↓51 to ↑14)
|Clarithromycina||500 mg BID||200 mg QD x 14 days; 200 mg BID x 14 days||15||↓31
(↓38 to ↓24)
(↓31 to ↓14)
(↓70 to ↓36)
(↑16 to ↑73)
(↑21 to ↑80)
|Ethinyl estradiola and Norethindronea||0.035 mg
(as Ortho-Novum® 1/35)
|200 mg QD x 14 days; 200 mg BID x 14 days||10||↓20
(↓33 to ↓3)
(as Ortho-Novum® 1/35)
(↓30 to ↓7)
(↓27 to ↓3)
|Depomedroxyprogesterone acetate||150 mg every 3 months||200 mg QD x 14 days; 200 mg BID x 14 days||32||⇔||⇔||⇔|
|Fluconazole||200 mg QD||200 mg QD x 14 days; 200 mg BID x 14 days||19||⇔||⇔||⇔|
|Ketoconazolea||400 mg QD||200 mg QD x 14 days; 200 mg BID x 14 days||21||↓72
(↓80 to ↓60)
(↓58 to ↓27)
|Methadonea||Individual Subject Dosing||200 mg QD x 14 days; 200 mg BID ?7 days||9||In a controlled pharmacokinetic trial with 9 subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 subjects. Methadone did not have any effect on nevirapine clearance.|
|Rifabutina||150 or 300 mg QD||200 mg QD x 14 days; 200 mg BID x 14 days||19||↓17
(↓2 to ↑40)
(↑9 to ↑51)
(↓16 to ↑84)
(↓2 to ↑68)
(↓14 to ↑74)
|Rifampina||600 mg QD||200 mg QD x 14 days; 200 mg BID x 14 days||14||↑11
(↓4 to ↑28)
|§ = Cmin below detectable level
of the assay
↑ = Increase, ↓ = Decrease, ⇔ = No Effect
aFor information regarding clinical recommendations, see DRUG INTERACTIONS.
bPediatric subjects ranging in age from 6 months to 12 years
cParallel group design; n for VIRAMUNE+lopinavir/ritonavir, n for lopinavir/ritonavir alone.
dParallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir PK are relative to atazanavir/ritonavir 300/100 mg alone.
eBased on between-trial comparison.
fBased on historical controls.
Because of the design of the drug interaction trials (addition of 28 days of VIRAMUNE therapy to existing HIV-1 therapy), the effect of the concomitant drug on plasma nevirapine steady-state concentrations was estimated by comparison to historical controls.
Administration of rifampin had a clinically significant effect on nevirapine pharmacokinetics, decreasing AUC and Cmax by greater than 50%. Administration of fluconazole resulted in an approximate 100% increase in nevirapine exposure, based on a comparison to historic data [see DRUG INTERACTIONS]. The effect of other drugs listed in Table 5 on nevirapine pharmacokinetics was not significant. No significant interaction was observed when tipranavir was co-administered with low-dose ritonavir and nevirapine.
Mechanism of Action
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases α, β, γ, or δ) are not inhibited by nevirapine.
The antiviral activity of nevirapine has been measured in a variety of cell lines including peripheral blood mononuclear cells, monocyte-derived macrophages, and lymphoblastoid cell lines. In an assay using human embryonic kidney 293 cells, the median EC50 value (50% inhibitory concentration) of nevirapine was 90 nM against a panel of 2923 wild-type isolates of HIV-1 that were primarily (93%) clade B clinical isolates from the United States. The 99th percentile EC50 value was 470 nM in this trial. The median EC50 value was 63 nM (range 14-302 nM, n=29) against clinical isolates of HIV-1 clades A, B, C, D, F, G, and H, and circulating recombinant forms CRF01_AE, CRF02_AG and CRF12_BF. Nevirapine had no antiviral activity in cell culture against group O HIV-1 isolates (n=3) or HIV-2 isolates (n=3) replicating in cord blood mononuclear cells. Nevirapine in combination with efavirenz exhibited strong antagonistic anti-HIV-1 activity in cell culture and was additive to antagonistic with the protease inhibitor ritonavir or the fusion inhibitor enfuvirtide. Nevirapine exhibited additive to synergistic anti-HIV-1 activity in combination with the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, saquinavir and tipranavir, and the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir and zidovudine. The anti-HIV-1 activity of nevirapine was antagonized by the anti-HBV drug adefovir and by the anti-HCV drug ribavirin in cell culture.
HIV-1 isolates with reduced susceptibility (100- to 250-fold) to nevirapine emerge in cell culture. Genotypic analysis showed mutations in the HIV-1 RT gene encoding Y181C and/or V106A substitutions depending upon the virus strain and cell line employed. Time to emergence of nevirapine resistance in cell culture was not altered when selection included nevirapine in combination with several other NNRTIs.
Phenotypic and genotypic changes in HIV-1 isolates from treatment-na´ve subjects receiving either nevirapine (n=24) or nevirapine and zidovudine (n=14) were monitored in Phase 1 and 2 trials ranging from 1 to 12 weeks or longer. After 1 week of nevirapine monotherapy, isolates from 3/3 subjects had decreased susceptibility to nevirapine in cell culture. One or more of the RT mutations resulting in amino acid substitutions K103N, V106A, V108I, Y181C, Y188C, and G190A were detected in HIV-1 isolates from some subjects as early as 2 weeks after therapy initiation. By week eight of nevirapine monotherapy, 100% of the subjects tested (n=24) had HIV-1 isolates with a greater than 100-fold decrease in susceptibility to nevirapine in cell culture compared to baseline, and had one or more of the nevirapineassociated RT resistance substitutions. Nineteen of these subjects (80%) had isolates with Y181C substitutions regardless of dose.
Genotypic analysis of isolates from antiretroviral-na´ve subjects experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine (trial 2NN) for 48 weeks showed that isolates from 8/25 and 23/46 subjects, respectively, contained one or more of the following NNRTI resistance-associated substitutions: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L, and M230L.
For trial 1100.1486, genotypic analysis was performed for baseline and on-therapy isolates from 23 and 34 subjects who experienced virologic failure in the VIRAMUNE XR and immediate-release VIRAMUNE treatment group, respectively. Nevirapine resistance-associated substitutions developed in the on-therapy isolates of 78% (18/23) of the subjects who had virologic failures in the VIRAMUNE XR treatment group and 88% (30/34) of the subjects in the immediate-release VIRAMUNE treatment group, respectively. The Y181C nevirapine resistance-associated substitution was found alone or in combination with other nevirapine resistance-associated substitutions (K101E, K103N, V106A, V108I, V179D/E/I, Y188 C/F/H/L/N, G190A, P225H, F227L, M230L) in isolates from 14 subjects failing VIRAMUNE XR treatment and 25 subjects failing immediate-release VIRAMUNE treatment. On-therapy isolates from 1 subject in VIRAMUNE XR treatment group developed a novel amino acid substitution Y181I and isolates from another subject in the immediate-release VIRAMUNE treatment group developed a novel amino acid substitution Y188N. Phenotypic analysis showed that Y188N and Y181I substitutions conferred 103- and 22-fold reductions in susceptibility to nevirapine, respectively.
Rapid emergence of HIV-1 strains which are cross-resistant to NNRTIs has been observed in cell culture. Nevirapine-resistant HIV-1 isolates were cross-resistant to the NNRTIs delavirdine, efavirenz, and etravirine. The Y188N conferred 22- and 7-fold reductions in susceptibility to delavirdine and efavirenz, respectively, but showed no decrease in susceptibility to etravirine. Similarly, the Y181I substitution reduced susceptibility to delavirdine and etravirine 3-and 8-fold, respectively, but did not reduce susceptibility to efavirenz. However, nevirapine-resistant isolates were susceptible to the NRTIs ddI and ZDV. Similarly, ZDV-resistant isolates were susceptible to nevirapine in cell culture.
Animal Toxicology And/Or Pharmacology
Animal studies have shown that nevirapine is widely distributed to nearly all tissues and readily crosses the blood-brain barrier.
The clinical efficacy of VIRAMUNE XR is based on 96-week data from an ongoing, randomized, double-blind, double-dummy Phase 3 trial (Trial 1100.1486, VERxVE) in treatment-na´ve subjects and on 48-week data in an ongoing, randomized, open-label trial in subjects who switched from immediate-release VIRAMUNE tablets administered twice daily to VIRAMUNE XR tablets administered once daily (Trial 1100.1526, TRANxITION).
Trial 1100.1486 (VERxVE) is a Phase 3 trial in which treatment-na´ve subjects received immediate-release VIRAMUNE 200 mg once daily for 14 days and then were randomized to receive either immediate-release VIRAMUNE 200 mg twice daily or VIRAMUNE XR 400 mg once daily. All subjects received tenofovir + emtricitabine as background therapy. Randomization was stratified by screening HIV-1 RNA level (less than or equal to 100,000 copies per mL and greater than 100,000 copies per mL). Subject demographic and baseline disease characteristics were balanced between the two treatment groups. With respect to demographics: 85% of the subjects were male, 75% were white, 20% were black, and approximately 29% were from North America. With respect to baseline disease characteristics: mean viral load was 4.7 log10 copies per mL, mean CD4+ cell count was 228 cells/mm³ and 73% of subjects had clade B HIV-1 subtype. Approximately two-thirds of the subjects had a baseline HIV-RNA level of less than or equal to 100,000 copies per mL.
Table 6 describes week 96 outcomes in the Trial 1100.1486 (VERxVE). These outcomes include all subjects who were randomized after the 14 day lead-in with immediate-release VIRAMUNE and received at least one dose of blinded study medication.
Table 6 : Outcomes at Week 96 in Trial 1100.1486
|Virologic Success - HIV RNA < 50 copies/mL||67%||69%|
|Virologic Failure #||18%||17%|
|No Virologic Data at Week 96 Window|
|Discontinued trial/study drug due to adverse event or death*||10%||8%|
|Discontinued trial/study drug for other reasons**||5%||5%|
|Missing data during window but on trial||< 1%||1%|
|#Includes subjects who changed
optimized background therapy (OBT) to new class or changed OBT not permitted
per protocol or due to lack of efficacy prior to Week 96, subjects who
discontinued prior to Week 96 for lack or loss of efficacy and subjects with
HIV RNA greater than or equal to 50 copies/mL in the Week 96 window.
*Includes subjects who discontinued due to adverse events or death at any time point from Day 1 through the Week 96 window if this resulted in no virologic data on treatment during the specified window.
**Other includes: withdrew consent, lost to follow-up, moved away, etc.
At 96 weeks, mean change from baseline in CD4+ cell count adjusting for baseline HIV-1 viral load stratum was 222 cells/mm³ and 244 cells/mm³ for the groups receiving immediate-release VIRAMUNE and VIRAMUNE XR, respectively.
Subjects Switching from Immediate-release VIRAMUNE to VIRAMUNE XR
Trial 1100.1526 (TRANxITION) is a Phase 3 trial to evaluate safety and antiviral activity of switching from immediate-release VIRAMUNE to VIRAMUNE XR. In this open-label trial, 443 subjects already on an antiviral regimen containing immediate-release VIRAMUNE 200 mg twice daily with HIV-1 RNA less than 50 copies per mL were randomized in a 2:1 ratio to VIRAMUNE XR 400 mg once daily or immediate-release VIRAMUNE 200 mg twice daily. Approximately half of the subjects had tenofovir+emtricitabine as their background therapy, with the remaining subjects receiving abacavir sulfate+lamivudine or zidovudine+lamivudine. Approximately half of the subjects had at least 3 years of exposure to immediate-release VIRAMUNE prior to entering the trial.
At 48 weeks after randomization in Trial 1100.1526, 91% of subjects receiving immediate-release VIRAMUNE 200 mg twice daily and 93% of subjects receiving VIRAMUNE XR 400 mg once daily continued to have HIV-1 RNA less than 50 copies per mL.
Trial 1100.1518 was an open-label, multiple-dose, non-randomized, crossover trial performed in 85 HIV-1 infected pediatric subjects 3 to less than 18 years of age who had received at least 18 weeks of immediate-release VIRAMUNE and had plasma HIV-1 RNA less than 50 copies per mL prior to trial enrollment. Subjects were stratified according to age (3 to less than 6 years, 6 to less than 12 years, and 12 to less than 18 years). Following a 10-day period with immediate-release VIRAMUNE, subjects were treated with VIRAMUNE XR tablets once daily in combination with other antiretrovirals for 10 days, after which steady-state pharmacokinetic parameters were determined. Forty of the 80 subjects who completed the initial part of the study were enrolled in an optional extension phase of the trial which evaluated the safety and antiviral activity of VIRAMUNE XR through a minimum of 24 weeks of treatment. Zidovudine or stavudine plus lamivudine were the most commonly used background therapies in subjects who entered the optional extension phase.
Baseline demographics included: 55% of the subjects were female, 93% were black, 7% were white, and approximately 84% were from Africa. Subjects had a median baseline CD4+ cell count of 925 cells/mm³ (range 207 to 2057 cells/mm³ ).
Of the 40 subjects who entered the treatment extension phase, 39 completed at least 24 weeks of treatment and one subject discontinued prematurely due to an adverse reaction. After 24 weeks or more of treatment with VIRAMUNE XR, all 39 subjects continued to have plasma HIV-1 RNA less than 50 copies per mL. Median CD4+ cell counts for the 3 to less than 6 year, 6 to less than 12 year, and 12 to less than 18 year age groups were 1113 cells/mm³ , 853 cells/mm³ , and 682 cells/mm³ , respectively. These CD4+ cell counts were similar to those observed at baseline.
Last reviewed on RxList: 2/6/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Viramune XR Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.